Article information
Full text is only aviable in PDF
References
[1.]
J.H. Olsen, K. Tangerud, L. Wermuth, K. Frederiksen, S. Friis.
Treatment with levodopa and risk for malignant melanoma.
Mov Disord, 22 (2007), pp. 1252-1257
[2.]
J.H. Olsen, F. Søren, K. Frederiksen.
Malignant melanoma and other types of cancer preceding Parkinson disease.
Epidemiology, 17 (2006), pp. 582-587
[3.]
R. Zanetti, D. Loria, S. Rosso.
Melanoma, Parkinson's disease and levodopa: Causal or spurious link? A review of the literature.
Melanoma Res, 16 (2006), pp. 201-206
[4.]
R. Zanetti, S. Rosso.
Levodopa and the risk of melanoma.
Lancet, 369 (2007), pp. 257-258
[5.]
R. Zanetti, S. Rosso, D.I. Loria.
Parkinson's disease and cancer.
Cancer Epidemiolol Biomarkers Prev, 16 (2007), pp. 1081
[6.]
J.F. Siple, D.C. Schneider, W.A. Wanlass, B.K. Rosenblatt.
Levodopa therapy and the risk of malignant melanoma.
Ann Pharmacother, 34 (2000), pp. 382-385
Copyright © 2010. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
